Roche’s tiragolumab flops in another Phase III lung cancer trial
Tiragolumab missed the chance to prove a survival benefit in SKYSCRAPER-01 adding to previous trial failures for the anti-TIGIT therapy.
Tiragolumab missed the chance to prove a survival benefit in SKYSCRAPER-01 adding to previous trial failures for the anti-TIGIT therapy.
What's Your Reaction?
